April 14 (Reuters) -
SANDOZ FILES ANTITRUST LITIGATION AGAINST AMGEN REGARDING PATIENT ACCESS TO ETANERCEPT BIOSIMILAR IN THE US
SANDOZ GROUP AG - FILES ANTITRUST LAWSUIT AGAINST AMGEN IN US
SANDOZ GROUP AG - ALLEGES AMGEN BLOCKED BIOSIMILAR COMPETITION
SANDOZ GROUP AG - SEEKS INJUNCTION TO PREVENT AMGEN FROM BLOCKING BIOSIMILAR COMPETITION
Source text: ID:nGNXnrD9Y
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.